Possession, Use, and Transfer of Select Agents and Toxins; Biennial Review of the List of Select Agents and Toxins
The CDC's biennial review of the select agents and toxins list may affect med-spas that use or store certain toxins (e.g., botulinum toxin). The review could add or remove agents, impacting compliance requirements.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Med-spas that possess, use, or transfer botulinum toxin or other potential select agents. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; final rule expected later in 2024.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The list of select agents and toxins is under review; changes may require new registration, security, or reporting measures.
Who it affects
Med-spas that possess, use, or transfer botulinum toxin or other potential select agents.
What you must do
Monitor the final rule for changes to the list and assess if your practice handles any newly regulated agents.
Deadline
No immediate deadline; final rule expected later in 2024.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication